EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR

Yiyi Lu, Lin Lin, Jiafei Lin, Beiying Wu, Gang Cai, Xuefeng Wang, Xuefei Ma

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05896-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yiyi Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. Hauptthemen laut MEDLINE: Janus Kinase 2, Myeloproliferative Disorders, Alleles, Clonal Evolution. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine "Guangci Clinical New Technology Launch Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The JAK2 V617F is a prevalent driver mutation in Philadelphia chromosome-negative myeloproliferative neoplasms (Ph − MPNs), significantly affecting disease progression, immunophenotype, and patient outcomes. The World Health Organization (WHO) guidelines highlight the JAK2 V617F mutation as one of the key diagnostic criterions for Ph − MPNs. In this study, we analyzed 283 MPN samples with the JAK2 V617F mutation to assess the effectiveness of three detection technologies: chip-based digital PCR (cdPCR), real-time quantitative PCR (qPCR), and next-generation sequencing (NGS). Additionally, we investigated the relationship between JAK2 V617F mutant allele burden (% JAK2 V617F) and various laboratory characteristics to elucidate potential implications in MPN diagnosis. Our findings demonstrated high conformance of cdPCR with qPCR/NGS for detecting % JAK2 V617F, but the mutant allele burdens detected by qPCR/NGS were lower than those detected by cdPCR. Moreover, the cdPCR exhibited high sensitivity with a limit of detection (LoD) of 0.08% and a limit of quantification (LoQ) of 0.2% for detecting % JAK2 V617F in MPNs. Clinical implications were explored by correlating % JAK2 V617F with various laboratory characteristics in MPN patients, revealing significant associations with white blood cell counts, lactate dehydrogenase levels, and particularly β2-microglobulin (β2-MG) levels. Finally, a case report illustrated the application of cdPCR in detecting low-allele burdens in a de novo chronic myeloid leukemia (CML) patient with a hidden JAK2 V617F subclone, which expanded during tyrosine kinase inhibitor (TKI) treatment. Our findings underscore the superior sensitivity and accuracy of cdPCR, making it a valuable tool for early diagnosis and monitoring clonal evolution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Myeloproliferative DisordersAllelesClonal EvolutionHumansFemaleMiddle AgedMaleAgedAdultReal-Time Polymerase Chain ReactionHigh-Throughput Nucleotide SequencingMutationAged, 80 and overPolymerase Chain ReactionOligonucleotide Array Sequence Analysis

Stichwörter der Autor:innen

JAK2 V617FChip-based digital PCRClonal evolutionMyeloproliferative neoplasms

Substanzen

Janus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China.
  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. wxf63@shsmu.edu.cn.
  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. mxf41013@rjh.com.cn.
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China…

Förderung

  • Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine "Guangci Clinical New Technology Launch Project

Zitieren

APA

Lu, Y., Lin, L., Lin, J., Wu, B., Cai, G., Wang, X., & Ma, X. (2024). Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR. Annals of Hematology. https://doi.org/10.1007/s00277-024-05896-5

Vancouver

Lu Y, Lin L, Lin J, Wu B, Cai G, Wang X, et al. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR. Annals of Hematology. 2024. doi:10.1007/s00277-024-05896-5

BibTeX
@article{Lu2024,
  author = {Lu, Yiyi and Lin, Lin and Lin, Jiafei and Wu, Beiying and Cai, Gang and Wang, Xuefeng and Ma, Xuefei},
  title = {Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05896-5}
}
Kostenlos starten →